Clinical trial
An Open-Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of Intravesical VB4-845 Injection in Patients With Non-Muscle Invasive Bladder Cancer
NCT04859751 is registered in ClinicalTrials.gov with Qilu Pharmaceutical Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of Intravesical VB4-845 Injection in Patients With Non-Muscle Invasive Bladder Cancer
- Lead sponsor
- Qilu Pharmaceutical Co., Ltd.
- Phase
- Phase 3
- Overall status
- Unknown status
- Start date
- March 23, 2021
- Completion date
- December 31, 2023
- Enrollment
- 53 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
non-muscle invasive bladder cancer